Board Member Leaves IRLAB for Another Assignment
GOTHENBURG, SE / ACCESSWIRE / December 31, 2021 / IRLAB Therapeutics (STO:IRLAB-A) (FRA:6IRA)
IRLAB (Nasdaq Stockholm: IRLAB A). Martin Nicklasson has announced his intention to leave the board in January 2022. The background to this decision is his new role as chairman of the board in another company.
According to IRLAB's articles of association, the board shall consist of at least three (3) and at most (10) members. When Nicklasson leaves the board, it will consist of five (5) members, and will thus continue to fulfill this requirement up to the next annual general meeting in May 2022, when a new board shall be chosen.
"On behalf of the board and shareholders I would like to extend a hearty thank-you to Martin for his valuable input to board activities this past year," says Gunnar Olsson, IRLAB's chairman of the board. "2021 has been a transformative period in IRLAB's development. Our successful license deal with mesdopetam and the regulatory approvals for the start of the Phase IIb study with pirepemat have given us a completely new basis for achieving IRLAB's long-term goals."
For more information
Gunnar Olsson, Chair of the board
Phone: +46 70 576 14 02
IRLAB is a Swedish research and development company that focuses on discovery and development of novel treatments in Parkinson's disease. The company's most advanced drug candidates, Mesdopetam (IRL790), licensed to Ipsen, and Pirepemat (IRL752), have completed Phase IIa studies and are designed to treat some of the most difficult symptoms related to Parkinson's disease: involuntary movements (PD-LIDs), psychosis (PD-P) and symptoms linked to cognitive decline such as impaired balance and increased risk of falls (PD-Falls). Through its proprietary research platform, the Integrative Screening Process (ISP), IRLAB has discovered and developed all its projects within Parkinson's disease and will have an ability to also discover drug candidates for other disorders of the central nervous system (CNS), where large and growing medical needs exist. In addition to the Phase IIb clinical candidates, the ISP platform has also generated several CNS programs that are now in preclinical phases. IRLAB is listed on Nasdaq Stockholm Main Market. More information is found on www.irlab.se.
SOURCE: IRLAB Therapeutics
View source version on accesswire.com:
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
Subscribe to releases from ACCESSWIRE
Subscribe to all the latest releases from ACCESSWIRE by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESSWIRE
SQL Technologies, Inc. dba Sky Technologies9.8.2022 14:34:46 CEST | Press release
SKYX Achieves Historic U.S. Standardization Approval Vote - a Major Milestone Towards Mandatory Status for Safety of Consumers and Professionals
Issuer Direct Corporation5.8.2022 23:17:35 CEST | Press release
Issuer Direct Reports Second Quarter 2022 Results
G Mining Ventures Corp.18.7.2022 12:02:20 CEST | Press release
G Mining Ventures Announces US$481 million Financing Package for Tocantinzinho Gold Project
Altamira Therapeutics23.6.2022 17:26:28 CEST | Press release
Altamira Therapeutics Achieves COVAMID Trial Target Enrollment for Bentrio in Acute COVID-19
Moderna, Inc.22.6.2022 14:03:42 CEST | Press release
Moderna Announces Bivalent Booster mRNA-1273.214 Demonstrates Potent Neutralizing Antibody Response Against Omicron Subvariants BA.4 And BA.5
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom